However, more specific anti-EPHA2 therapeutic options, such as ALW-II-41–27, candidate 4a, and GLPG1790, having emerged in recent years, displaying good in vitro and in vivo efficacy against EPHA2 phosphorylation and affecting epithelial–mesenchymal transition (EMT) and migration in CRC, non-small cell lung cancer (NSCLC), and glioblastoma (Amato et al. 2014; Colapietro et al. 2022; Heinzlmeir et al. 2017). This evidence concerns the gene EPHA2 and glioblastoma.